| Name | Title | Contact Details |
|---|
Founded in 1975, CHS is the industry's trusted provider of onsite health centers and national examination programs.
3LAB Inc is a Englewood, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We empower the most underserved stakeholder in the healthcare system – the family caregiver. While training programs exist for home health aides or nurses to help manage care of the elderly, family members, who provide 80%+ of care to loved ones aging-in-place, have limited access to training. For example, actionable education like how to prevent falls in the house, safely transfer from a bed or chair, or manage difficult behaviour when a loved one has dementia. Recognizing that this content exists but isn`t available to families, Trualta adapted professional-level healthcare training for the family member audience. We deliver the training via an informal and interactive online learning environment, and tailor the learning to each caregiver`s situation. The program incentivizes engagement with a rewards system, and users can redeem rewards for helpful products and services. Our customers, healthcare payers and providers in Canada & the US, offer Trualta at point-of-care to better enable families to transition aging loved ones from hospital to home, and sustain independent living. Through clinical validation studies in the US and Canada, we are linking participation in Trualta`s program to improved outcomes and reduced costs. We are a proud resident company of the Biomedical Zone in downtown Toronto and the Invest Ottawa Accelerator program. If you are passionate about educating and enabling families to improve care for our aging population, drop us a note at info@trualta.com – we`d love to hear from you.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
With nearly 5,000 employees comprising Acadian Ambulance, Acadian Air Med, National EMS Academy, Acadian Total Security, Safety Management Systems and Executive Aircraft Charter Service, Acadian Companies provides a diverse suite of services that offer the very best support and education in health, safety and transportation.